In summation, these findings underscore the anti-hepatocellular carcinoma (HCC) potential of malvidin, which is associated with its inhibition of MAPK, Akt/PTEN, and MMP pathways [128]. This evidence concerns the gene PTEN and hepatocellular carcinoma.